Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
endocrine system diseases | D004700 |
Brand Name | Status | Last Update |
---|---|---|
actoplus met | New Drug Application | 2025-03-27 |
actos | New Drug Application | 2025-03-28 |
alogliptin and pioglitazone | NDA authorized generic | 2024-08-13 |
duetact | New Drug Application | 2025-03-27 |
oseni | New Drug Application | 2025-02-28 |
pioglitazone | ANDA | 2025-05-17 |
pioglitazone and glimepiride | NDA authorized generic | 2021-12-16 |
pioglitazone and metformin | ANDA | 2016-11-23 |
pioglitazone hydrochloride | ANDA | 2025-05-17 |
pioglitazone hydrochloride and metformin hydrochloride | ANDA | 2025-02-27 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Alogliptin Benzoate / Pioglitazone Hydrochloride, Oseni, Takeda Pharms Usa | |||
8637079 | 2029-06-04 | DP | |
7807689 | 2028-06-27 | DS, DP | U-1337 |
8173663 | 2025-03-15 | U-1338 | |
8288539 | 2025-03-15 | DP | |
Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met, Takeda Pharms Usa | |||
9320714 | 2029-02-03 | DP | |
9101660 | 2027-01-22 | DP | |
Glimepiride / Pioglitazone Hydrochloride, Duetact, Takeda Pharms Usa | |||
8071130 | 2028-06-08 | DP | |
7700128 | 2027-01-30 | DP | |
Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met Xr, Takeda Pharms Usa | |||
7785627 | 2026-07-31 | DP | |
7959946 | 2026-07-31 | DP | |
8470368 | 2023-09-19 | DP | |
8668931 | 2023-09-19 | DP | |
9060941 | 2023-09-19 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Pioglitazone |
INN | pioglitazone |
Description | Pioglitazone is a member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. It has a role as an insulin-sensitizing drug, an EC 2.7.1.33 (pantothenate kinase) inhibitor, a xenobiotic, an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor, a ferroptosis inhibitor, a cardioprotective agent, a PPARgamma agonist, an antidepressant, a geroprotector and a hypoglycemic agent. It is a member of thiazolidinediones, an aromatic ether and a member of pyridines. |
Classification | Small molecule |
Drug class | peroxisome proliferator activiating receptor (PPAR) agonists (thiazolidene derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1 |
PDB | — |
CAS-ID | 111025-46-8 |
RxCUI | — |
ChEMBL ID | CHEMBL595 |
ChEBI ID | 8228 |
PubChem CID | 4829 |
DrugBank | DB01132 |
UNII ID | X4OV71U42S (ChemIDplus, GSRS) |